Article Versions Notes

Morovat A, Weerasinghe G, Nesbitt V, Hofer M, Agnew T, Quaghebeur G, Sergeant K, Fratter C, Guha N, Mirzazadeh M, et al. Use of FGF-21 as a Biomarker of Mitochondrial Disease in Clinical Practice. Journal of Clinical Medicine. 2017; 6(8):80. https://doi.org/10.3390/jcm6080080

Morovat, Alireza, Gayani Weerasinghe, Victoria Nesbitt, Monika Hofer, Thomas Agnew, Geralrine Quaghebeur, Kate Sergeant, Carl Fratter, Nishan Guha, Mehdi Mirzazadeh, and et al. 2017. "Use of FGF-21 as a Biomarker of Mitochondrial Disease in Clinical Practice" Journal of Clinical Medicine 6, no. 8: 80. https://doi.org/10.3390/jcm6080080

Morovat, A., Weerasinghe, G., Nesbitt, V., Hofer, M., Agnew, T., Quaghebeur, G., Sergeant, K., Fratter, C., Guha, N., Mirzazadeh, M., & Poulton, J. (2017). Use of FGF-21 as a Biomarker of Mitochondrial Disease in Clinical Practice. Journal of Clinical Medicine, 6(8), 80. https://doi.org/10.3390/jcm6080080